From oral IL-23 blockade in UC to sex-specific FIT thresholds and a swallowable Barrett’s test, these are 7 trials from ACG 2026 clinicians should know.
News|Articles|November 5, 2025
Conference Preview: AASLD The Liver Meeting 2025
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
View slated expert interviews and 5 clinical trials to watch at AASLD The Liver Meeting 2025.
Advertisement
Advertisement
The American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025 kicks off in Washington, DC, on Friday, November 7, 2025. The 5-day conference boasts the latest research shaping the future of hepatology, including groundbreaking studies, clinical insights, and innovations from investigators around the world.
Related to this article
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.
Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Advertisement
Advertisement